Skip to content

Insider · CIK 0001700917

Pravin Dugel

officerdirector

Files at OCUL (OCULAR THERAPEUTIX, INC). First filing Nov 27, 2024, latest Feb 25, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 7
$0 bought, $2.3M sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

OCUL: OCULAR THERAPEUTIX, INC

OCULOct 9, 2026 · close 7.54

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
21Weak
OCULsell 610b5-1
OCULAR THERAPEUTIX, INC
$166k
20,056 shares
-1%+42% from low-48% from high
35Weak
OCULsell 610b5-1
OCULAR THERAPEUTIX, INC
$1.1M
124,882 shares
-4%+53% from low-44% from high
23Weak
OCULsell 410b5-1
OCULAR THERAPEUTIX, INC
$235k
19,530 shares
-1%+104% from low-11% from high
23Weak
OCULsell 510b5-1
OCULAR THERAPEUTIX, INC
$259k
21,494 shares
-1%+100% from low-6% from high
21Weak
OCULsell 510b5-1
OCULAR THERAPEUTIX, INC
$152k
21,219 shares
-1%+23% from low-36% from high
21Weak
OCULsell 310b5-1
OCULAR THERAPEUTIX, INC
$148k
21,475 shares
-1%-
22Weak
OCULsell 410b5-1
OCULAR THERAPEUTIX, INC
$186k
20,680 shares
-3%-

Planned sales

Form 144 notices this insider filed before selling restricted or control stock, newest first.

FiledCompanySharesValueSale datePast 3 months
Nov 25, 2024 OCUL
OCULAR THERAPEUTIX, INC.
2,897
0.00% of outstanding
$26kNov 25, 2024none
Nov 25, 2024 OCUL
OCULAR THERAPEUTIX, INC.
17,783
0.01% of outstanding
$160kNov 25, 2024none

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Feb 23, 2026OCUL
OCULAR THERAPEUTIX, INC
SOpen-market sale
Common Stock10b5-1
-20,056$8.28$166k3,013,022Feb 25, 2026
Feb 12, 2026OCUL
OCULAR THERAPEUTIX, INC
SOpen-market sale
Common Stock10b5-1
-124,882$9.04$1.1M3,033,078Feb 17, 2026
Nov 24, 2025OCUL
OCULAR THERAPEUTIX, INC
SOpen-market sale
Common Stock10b5-1
-19,530$12.04$235k3,157,960Nov 26, 2025
Nov 26, 2025OCUL
OCULAR THERAPEUTIX, INC
GGift
Common Stockindirect: By spouse10b5-1
-49,754$0.00$00Nov 26, 2025
Nov 26, 2025OCUL
OCULAR THERAPEUTIX, INC
GGift
Common Stockindirect: By Pravin Dugel 2024 Irrevocable Trust10b5-1
+49,754$0.00$0300,115Nov 26, 2025
Sep 9, 2025OCUL
OCULAR THERAPEUTIX, INC
GGift
Common Stock
-49,754$0.00$03,177,490Sep 11, 2025
Sep 9, 2025OCUL
OCULAR THERAPEUTIX, INC
GGift
Common Stockindirect: By spouse
+49,754$0.00$049,754Sep 11, 2025
Aug 25, 2025OCUL
OCULAR THERAPEUTIX, INC
SOpen-market sale
Common Stock10b5-1
-21,494$12.04$259k3,227,244Aug 27, 2025
Apr 28, 2025OCUL
OCULAR THERAPEUTIX, INC
GGift
Common Stock
-200,332$0.00$03,298,767Aug 13, 2025
Jun 12, 2025OCUL
OCULAR THERAPEUTIX, INC
GGift
Common Stock
-50,029$0.00$03,248,738Aug 13, 2025
Aug 11, 2025OCUL
OCULAR THERAPEUTIX, INC
GGift
Common Stockindirect: By Pravin Dugel 2024 Irrevocable Trust
+250,361$0.00$0250,361Aug 13, 2025
Jun 11, 2025OCUL
OCULAR THERAPEUTIX, INC
AGrant or award
Performance Stock Option (Right to Buy)derivative
+2,750,000$0.00$02,750,000Jun 13, 2025
May 23, 2025OCUL
OCULAR THERAPEUTIX, INC
SOpen-market sale
Common Stock10b5-1
-21,219$7.18$152k3,499,099May 27, 2025
Feb 24, 2025OCUL
OCULAR THERAPEUTIX, INC
SOpen-market sale
Common Stock10b5-1
-21,475$6.87$148k3,520,318Feb 26, 2025
Feb 11, 2025OCUL
OCULAR THERAPEUTIX, INC
AGrant or award
Common Stock
+1,250,000$0.00$02,041,793Feb 13, 2025
Feb 11, 2025OCUL
OCULAR THERAPEUTIX, INC
AGrant or award
Common Stock
+1,500,000$0.00$03,541,793Feb 13, 2025
Nov 25, 2024OCUL
OCULAR THERAPEUTIX, INC
SOpen-market sale
Common Stock10b5-1
-20,680$9.01$186k791,793Nov 27, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Pravin Dugel: insider trades and track record | InsiderTell